Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone (+P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC)
| Autor: | Gerhardt Attard, Gurpreet Kapoor, Fabio Calabrò, Weibke Arlt, Anna Wingate, Daniel Wetterskog, Bertrand F. Tombal, Cora N. Sternberg, Weimin Li, Lorraine Barwell, Michael Gormley, Axel S. Merseburger, Florence Lefresne, Dong Shen, Robert Jones, Susan Feyerabend, Alfredo Berruti, Mansour T. A. Sharabiani, Anuradha Jayaram |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry Abiraterone acetate Phases of clinical research Castration resistant medicine.disease Androgen receptor chemistry.chemical_compound Prostate cancer chemistry Prednisone Internal medicine medicine business Dexamethasone medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 36:5067-5067 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 5067Background: pAR gene aberrations in mCRPC patients (pts) may be associated with worse outcome on AA+P/D. Methods: This was an international, multi-institutional, open-label phase 2 study of AA ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|